COMPANY PROFILE

Adjuvance Technologies

Explore full profile

Adjuvance Technologies is a privately held biopharmaceutical company

Lincoln, United StatesFounded 2009Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Adjuvance Technologies

Adjuvance Technologies is a privately held biopharmaceutical company focused on advancing vaccine efficacy through the development of cutting-edge adjuvant technologies. The company operates in the healthcare and pharmaceutical markets, primarily serving research institutions, pharmaceutical companies, and government agencies. Adjuvance Technologies specializes in synthesizing saponin adjuvants like QS-21, which are critical components in vaccines to boost immune responses. The business model revolves around research and development, securing funding through grants and investments, and forming strategic partnerships for product development and commercialization. Revenue is generated through contract funding, licensing agreements, and milestone payments from collaborative projects.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2009
Headquarters: Lincoln, United States
Open positions: None listed
Dealroom signal: 51.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jan 2020	$20M	$80M	Morningside	—
ANGELEquity / VC	Jan 2019	—	—	Nebraska Angel Network	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Adjuvance Technologies website traffic

Latest recorded traffic for Adjuvance Technologies is 290 monthly website visits, down 92.9% over the last three months.

Latest monthly visits290 3-month web change-92.9%

Monthly website visitsJan 2020–Dec 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
I-I-vitaeProviding a science-backed program alternative to assisted reproductive treatments	Brescia, Italy	Closed	2	—	—
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational
PBPhagoMed BiopharmaDevelops endolysins and phage as therapeutics	Vienna, Austria	Acquired
DRDropliteDeveloping a novel lab-on-a-chip diagnostics device that enables a rapid and accurate way to test relevant diseases and health conditions in both humans and animals	Barcelona, Spain	Closed
ILIndee LabsNon-viral intracellular delivery platform for engineered cell therapies	Berkeley, United States	Operational
DGDestina GeonomicsAims to transform how miRNAs are detected, providing simpler tools for health care and drug development professionals	Granada, Spain	Operational
STSenolytic TherapeuticsA discovery-stage biotech developing novel medicines that target senescent cells	Barcelona, Spain	Closed
SFStevia FirstWe are an agricultural biotechnology company focused initially on stevia	United States	Operational